{
    "id": 14107,
    "fullName": "FH inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "FH inact mut indicates that this variant results in a loss of function of the Fh protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2271,
        "geneSymbol": "FH",
        "terms": [
            "FH",
            "FMRD",
            "HLRCC",
            "HsFH",
            "LRCC",
            "MCL",
            "MCUL1"
        ]
    },
    "variant": "inact mut",
    "createDate": "11/20/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7238,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) decreased viablility of FH-deficient tumor cell lines derived from patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) in culture (PMID: 25490448).",
            "molecularProfile": {
                "id": 14363,
                "profileName": "FH inact mut"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3971,
                    "pubMedId": 25490448,
                    "title": "Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25490448"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14363,
            "profileName": "FH inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 7094,
                    "name": "Vandetanib",
                    "profileName": "FH inact mut"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}